As UK Cystic Fibrosis Patients Push for Drug Coverage, a Girl That Died too Soon Becomes the Face of the Campaign
Walkerssk / Pixabay

As UK Cystic Fibrosis Patients Push for Drug Coverage, a Girl That Died too Soon Becomes the Face of the Campaign

According to a story from express.co.uk, Elle Morris was only 11 years old when she died from a severe lung infection. Elle was born with cystic fibrosis, a serious genetic…

Continue Reading As UK Cystic Fibrosis Patients Push for Drug Coverage, a Girl That Died too Soon Becomes the Face of the Campaign

Early Trial Data Suggests Safety and Potential Efficacy of Experimental Drug in Treating Advanced Hepatocellular Carcinoma

According to a story from BioPortfolio, the biotechnology company Tiziana Life Sciences plc recently announced encouraging results from an interim safety review of the company's Phase 2a clinical trial. This…

Continue Reading Early Trial Data Suggests Safety and Potential Efficacy of Experimental Drug in Treating Advanced Hepatocellular Carcinoma
Recent Study Indicates That SPINRAZA can Benefit Patients with Late-Onset Spinal Muscular Atrophy
Pexels / Pixabay

Recent Study Indicates That SPINRAZA can Benefit Patients with Late-Onset Spinal Muscular Atrophy

According to a story from globenewswire.com, the biotechnology company Biogen recently released data from an open label study that was testing the company's spinal muscular atrophy drug nusinersen (marketed as…

Continue Reading Recent Study Indicates That SPINRAZA can Benefit Patients with Late-Onset Spinal Muscular Atrophy

New Drug Under Review by the FDA to Treat the Most Lethal Form of Spinal Muscular Atrophy

  According to an article in Biospace, the FDA is currently reviewing data from the Phase III STRIVE clinical trial for possible approval of Zolgensma as gene therapy for spinal…

Continue Reading New Drug Under Review by the FDA to Treat the Most Lethal Form of Spinal Muscular Atrophy

Fulcrum Therapeutics Acquires Experimental Facioscapulohumeral Muscular Dystrophy Drug

According to a press release from Massachusetts-based biotech company Fulcrum Therapeutics, the company has successfully secured global commercialization rights of GlaxoSmithKline-developed experimental facioscapulohumeral muscular dystrophy (FSHD) drug losmapimod. Losmapimod, an…

Continue Reading Fulcrum Therapeutics Acquires Experimental Facioscapulohumeral Muscular Dystrophy Drug

Phase 2a Clinical Trial for Investigational Cell Therapy Now Recruiting Primary Sclerosing Cholangitis and Autoimmune Hepatitis Patients

Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are both rare and chronic liver diseases. They cause the bile ducts in the liver to become inflamed, resulting in severe liver damage.…

Continue Reading Phase 2a Clinical Trial for Investigational Cell Therapy Now Recruiting Primary Sclerosing Cholangitis and Autoimmune Hepatitis Patients

Orphan Drug Designation Given to New Potential Oral Therapy for Hypereosinophilic Syndrome

Hypereosinophilic Syndrome Hypereosinophilic syndrome (HES) is a rare disease which causes high levels of white blood cells in the body. These cells are called eosinophils, and they're essential for proper…

Continue Reading Orphan Drug Designation Given to New Potential Oral Therapy for Hypereosinophilic Syndrome

Study Indicates More Research is Needed on Transgender Acute Myeloid Leukemia Patients to Improve Patient Care

In a world that is just beginning to make space for the open discussion of transgender individual's life experiences, there's still a huge gap in the conversation regarding healthcare. This…

Continue Reading Study Indicates More Research is Needed on Transgender Acute Myeloid Leukemia Patients to Improve Patient Care
Phenylketonuria Patient Didn’t Receive Life-Altering Treatment for 10 Years, Alludes to Bigger Problem
source: pixabay.com

Phenylketonuria Patient Didn’t Receive Life-Altering Treatment for 10 Years, Alludes to Bigger Problem

Within the pharmaceutical industry, we need 1) better policies for patients and 2) improved communication/education of the policies that do exist for patients and the rights that they have. Ultimately,…

Continue Reading Phenylketonuria Patient Didn’t Receive Life-Altering Treatment for 10 Years, Alludes to Bigger Problem

Diagnostic Timeline for Lysosomal Storage Disorders like Fabry Disease Significantly Reduced in South Africa

The Problem Lysosomal storage disorders (LSDs) affect approximately one out of every 7,000 people. There are around 50 different types of LSDs. These include Fabry disease, Batten disease, Gaucher disease,…

Continue Reading Diagnostic Timeline for Lysosomal Storage Disorders like Fabry Disease Significantly Reduced in South Africa